Medscape

A Novel Treatment for Glioblastoma

Cilengitide is currently the lead prototype in the RGD peptidomimetic category of anti-integrin therapies, and is under investigation for several cancers, including GBM (and is currently the only anti ...
ascopubs.org

Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II ...

A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. Background: Expected median survival is poor for patients with glioblastoma multiforme (GBM).
Nature

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

Novel therapies are needed to improve the poor prognosis of patients with recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN). ADVANTAGE is a phase I/II, multicentre study ...
Business Wire

EMD Serono: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in Patients With Newly Diagnosed Glioblastoma

Cilengitide is currently being investigated in glioblastoma – a very aggressive type of brain tumor – in a Phase III trial (CENTRIC) and in a Phase II trial (CORE). An additional Phase I/II trial is ...
Nature

Will integrin inhibitors have proangiogenic effects in the clinic?

In a comprehensive analysis, Reynolds et al. 1 recently reported that RGD-mimetic agents such as cilengitide may, under certain experimental conditions, promote rather than inhibit angiogenesis. They ...